Q-omics provides the consensus-scored FAM133A profile across patient tissues and cancer cell-line models. FAM133A expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, FAM133A is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, FAM133A RNA expression shows 14,820 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, THCA, and UVM as cancer lineages where FAM133A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM133A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM133A survival associations across molecular data types. FAM133A RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM133A RNA expression–survival associations across cancer types. High FAM133A expression shows unfavorable associations in KIRP, UCEC, BLCA and SCLC, but favorable associations in OV and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for FAM133A RNA expression.
This table summarizes FAM133A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for FAM133A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM133A shows lower tumor expression in THCA, KICH, COAD and KIRC and higher tumor expression in LIHC and LUAD. The THCA box plot shows higher FAM133A RNA expression in normal versus tumor tissue (log2 FC = −0.260, t-test p < 0.001).
This table shows molecular features associated with FAM133A in patient tissues and cancer cell lines. In patient samples, FAM133A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM133A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BONE.
